Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real AssetSeeking Alpha • 06/26/26
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsGlobeNewsWire • 06/15/26
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock UpZacks Investment Research • 06/04/26
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAGlobeNewsWire • 06/03/26
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/05/26
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?Zacks Investment Research • 04/23/26
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionGlobeNewsWire • 04/16/26
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockGlobeNewsWire • 04/15/26
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis TranscriptSeeking Alpha • 04/13/26
Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis ResultsInvestors Business Daily • 04/13/26
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsGlobeNewsWire • 04/13/26
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026GlobeNewsWire • 04/10/26
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/11/26